Early trial tests new combo for Tough-to-Treat sarcomas
NCT ID NCT03123276
Summary
This study aimed to find a safe dose for a new two-drug combination (pembrolizumab and gemcitabine) for patients with advanced leiomyosarcoma or undifferentiated pleomorphic sarcoma, two aggressive types of soft tissue cancer. It involved 25 patients and focused primarily on identifying side effects and determining the highest dose that could be given safely. The goal was to see if combining these drugs could be a tolerable approach for controlling these difficult cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Marsden
London, United Kingdom
Conditions
Explore the condition pages connected to this study.